Royalty Pharma's stock is experiencing shifts in the market as it recently hit a
52-week low at $25.1. Nonetheless, the asset is recommended as a
high-yield dividend stock to purchase and hold for long durations. Reputed management firms including
State Street Corp and
Executive Wealth Management have adjusted their holdings while
Jim Cramer commented that the stock has been 'a bit of a bust'. Despite hitting lows, some believe that
Royalty Pharma is a bargain buy at this point. Furthermore,
Royalty Pharma's Q3 results showed promising
15% revenue growth and $1.2 billion deployment. The company secured a critical
$125 million RYTELO deal and is focused on strategic investments in
FDA-approved Cancer drugs. Q3 earnings revealing a substantial increase in EPS from US$0.16 in 2025 to US$0.92 in 2024. Moreover, the company has struck multiple royalty funding agreements including a
$350 million deal with Syndax Pharmaceuticals.
Royalty Pharma Stocks News Analytics from Tue, 17 Aug 2021 07:00:00 GMT to Fri, 13 Dec 2024 17:44:00 GMT -
Rating 4
- Innovation 5
- Information 8
- Rumor -3
